[
  {
    "ts": null,
    "headline": "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=03c4744cf93fee283d828b1f7d84602fbfb96f72b01e18a7b32ed81f300c65c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751635803,
      "headline": "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?",
      "id": 135755838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=03c4744cf93fee283d828b1f7d84602fbfb96f72b01e18a7b32ed81f300c65c7"
    }
  },
  {
    "ts": null,
    "headline": "Japan Tissue Diagnostics Market to Hit US$ 234 Million by 2030 | Aging Population Spurs Demand for Advanced Tissue Diagnostics in Japan",
    "summary": "The Japanese tissue diagnostics market is projected to climb to US$ 234 Million by 2030, driven by aging demographics and increasing prevalence of chronic diseases. Key market innovations include digital pathology and growing use of automated systems. Major players include Abbott and Sakura Finetek Japan.Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The \"Japan IVD Tissue Diagnostics Market (By Segment - Pre-Analytical Processing, H&E Staining, Special Staining, IHC Staining, ISH Staining, Digital Pa",
    "url": "https://finnhub.io/api/news?id=d42bc19267a3b18029a9d7eb387d38ddfa975a4e0eb452b0fede1a886eaa6f2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751616060,
      "headline": "Japan Tissue Diagnostics Market to Hit US$ 234 Million by 2030 | Aging Population Spurs Demand for Advanced Tissue Diagnostics in Japan",
      "id": 135755839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Japanese tissue diagnostics market is projected to climb to US$ 234 Million by 2030, driven by aging demographics and increasing prevalence of chronic diseases. Key market innovations include digital pathology and growing use of automated systems. Major players include Abbott and Sakura Finetek Japan.Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The \"Japan IVD Tissue Diagnostics Market (By Segment - Pre-Analytical Processing, H&E Staining, Special Staining, IHC Staining, ISH Staining, Digital Pa",
      "url": "https://finnhub.io/api/news?id=d42bc19267a3b18029a9d7eb387d38ddfa975a4e0eb452b0fede1a886eaa6f2d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott’s future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. […]",
    "url": "https://finnhub.io/api/news?id=312782db0dc6cc6e2f06bb0918a6ab511be80463cee6da55dceee1c1664783e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751611386,
      "headline": "Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas",
      "id": 135747130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott’s future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. […]",
      "url": "https://finnhub.io/api/news?id=312782db0dc6cc6e2f06bb0918a6ab511be80463cee6da55dceee1c1664783e9"
    }
  }
]